Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Elevated in vivo markers of presynaptic striatal dopamine activity have been a consistent finding in schizophrenia, and include a large effect size elevation in dopamine synthesis capacity. However, it is not known if the dopaminergic dysfunction is limited to the striatal terminals of dopamine neurons, or is also evident in the dopamine neuron cell bodies, which mostly originate in the substantia nigra. The aim of our studies was therefore to determine whether dopamine synthesis capacity is altered in the substantia nigra of people with schizophrenia, and how this relates to symptoms. In a post-mortem study, a semi-quantitative analysis of tyrosine hydroxylase staining was conducted in nigral dopaminergic cells from post-mortem tissue from patients with schizophrenia (n = 12), major depressive disorder (n = 13) and matched control subjects (n = 13). In an in vivo imaging study, nigral and striatal dopaminergic function was measured in patients with schizophrenia (n = 29) and matched healthy control subjects (n = 29) using (18)F-dihydroxyphenyl-L-alanine ((18)F-DOPA) positron emission tomography. In the post-mortem study we found that tyrosine hydroxylase staining was significantly increased in nigral dopaminergic neurons in schizophrenia compared with both control subjects (P < 0.001) and major depressive disorder (P < 0.001). There was no significant difference in tyrosine hydroxylase staining between control subjects and patients with major depressive disorder, indicating that the elevation in schizophrenia is not a non-specific indicator of psychiatric illness. In the in vivo imaging study we found that (18)F-dihydroxyphenyl-L-alanine uptake was elevated in both the substantia nigra and in the striatum of patients with schizophrenia (effect sizes = 0.85, P = 0.003 and 1.14, P < 0.0001, respectively) and, in the voxel-based analysis, was elevated in the right nigra (P < 0.05 corrected for family wise-error). Furthermore, nigral (18)F-dihydroxyphenyl-L-alanine uptake was positively related with the severity of symptoms (r = 0.39, P = 0.035) in patients. However, whereas nigral and striatal (18)F-dihydroxyphenyl-L-alanine uptake were positively related in control subjects (r = 0.63, P < 0.001), this was not the case in patients (r = 0.30, P = 0.11). These findings indicate that elevated dopamine synthesis capacity is seen in the nigral origin of dopamine neurons as well as their striatal terminals in schizophrenia, and is linked to symptom severity in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These techniques indicate that striatal dopamine synthesis, storage and release are elevated in patients with psychosis compared to healthy controls (HC) (45-48) with large effect sizes (49).”
From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567 · cited 1×
“A Patlak graphical analysis was used to calculate the influx constant (K cer i value) for the specific uptake of 18 F-DOPA in the regions of interest relative to uptake in the reference region (Patlak et al., 1983).”
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Self-citationDopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018 · cited 1×
“The dopamine hypothesis of schizophrenia proposes that subcortical dopamine dysfunction underlies the illness (Davis et al., 1991; Howes and Kapur, 2009).”
Haber, S. N., Fudge, J. L., & McFarland, N. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-06-02369.2000 · Cited by 1,610 · cited 1×
“…evidence indicates that these alterations in dopamine function are particularly apparent in the associative subdivision of the striatum (Howes et al., 2009b; Kegeles et al., 2010), which predominantly receives projections from the substantia nigra (Haber et al., 2000, 2006; Joel and Weiner, 2000).”
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 2×
“…al., 2012; Roiser et al., 2012; Yoon et al., 2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an…”
Ollinger, J. M., & Fessler, J. A. (1997) · IEEE Signal Processing Magazine · doi:10.1109/79.560323 · Cited by 1,167
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 2×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 2×
“…2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an increase in midbrain dopamine neuron…”
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967 · cited 3×
“In the schizophrenia group the mean (SD) symptom severity scores were: total symptoms = 77.6 (47.6); positive symptoms = 38.3 (30); affective symptoms = 2.0 (3.9); negative symptoms = 31.9 (22.9).”
InfluentialSelf-citationIncreased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803 · cited 1×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Research works printed but not linked: 3
- Andreasen NC. Comprehensive assessment of symptoms and history. Iowa: University of Iowa College of Medicine; 1987. [Google Scholar]
- Asselin MCH, Howes OD, Osman S, Yau K, Grasby PM. Increase in striatal f-DOPA influx constants in patients at ultra high risk of psychosis are not due to changes in plasma OMFD concentrations. J Cereb Blood Flow Metab. 2007;27:PO01–03M. [Google Scholar]
- Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry. 2012b;69:776–86. doi: 10.1001/archgenpsychiatry.2012.169. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Schizophrenia, dopamine and the striatum: From biology to symptoms
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.004 · Cited by 763
Self-citationGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“…with some studies not finding significant differences from controls (Dao-Castellana et al., 1997; Elkashef et al., 2000; Shotbolt et al., 2011) whilst others have detected significant elevations (Howes et al., 2013a; McGowan et al., 2004; Meyer-Lindenberg et al., 2002; Reith et al., 1994).”
BackgroundSelf-citationThe Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 601
Self-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Self-citationSlifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J. L., Narendran, R., Gil, R., Hackett, E., Girgis, R., Ojeil, N., Moore, H., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2414 · Cited by 398
Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
Kesby, J., Eyles, D., McGrath, J., & Scott, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0071-9 · Cited by 352
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
“In early imaging studies based on positron emission tomography (PET), patients with schizophrenia showed increased dopamine activity in the striatum [5] and the midbrain origin of neurons [6] compared with the controls.”
BackgroundPathway-Specific Dopamine Abnormalities in Schizophrenia
Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2104 · Cited by 297
“The finding of increased Ki cer (91) is potentially susceptible to group differences in cerebellar concentration of [(18)F]DOPA.”
McCutcheon, R., Beck, K., Jauhar, S., & Howes, O. D. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx180 · Cited by 305
Self-citationNeuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain
Cassidy, C. M., Zucca, F. A., Girgis, R. R., Baker, S. C., Weinstein, J. J., Sharp, M. E., Bellei, C., Valmadre, A., Vanegas, N., Kegeles, L. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807983116 · Cited by 244
“Because postmortem studies have found normal counts of SN dopamine neurons in psychotic patients (24, 29) together with abnormal markers of dopamine function in these neurons (24, 50, 51) (but see ref.”
BackgroundJauhar, S., Nour, M. M., Veronese, M., Rogdaki, M., Bonoldi, I., Azis, M., Turkheimer, F., McGuire, P., Young, A. H., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2943 · Cited by 233
Self-citationSchizophrenia: from neurochemistry to circuits, symptoms and treatments
Howes, O. D., Bukala, B. R., & Beck, K. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00904-0 · Cited by 192
“Initial post-mortem and neuroimaging studies indicate that levels of dopamine markers are altered in the midbrains of people with schizophrenia relative to healthy control individuals 9–11 .”
Self-citationBaumeister, D., Sedgwick, O., Howes, O., & Peters, E. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2016.10.010 · Cited by 220
Self-citationAnhedonia in depression and schizophrenia: A transdiagnostic challenge
Lambert, C., Da Silva, S., Ceniti, A. K., Rizvi, S. J., Foussias, G., & Kennedy, S. H. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12854 · Cited by 155
Dopamine and the aberrant salience hypothesis of schizophrenia
Howes, O. D., & Nour, M. M. (2016) · World Psychiatry · doi:10.1002/wps.20276 · Cited by 144
Self-citationDysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
Sonnenschein, S. F., Gomes, F. V., & Grace, A. A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00613 · Cited by 158
Kim, E., Howes, O. D., Veronese, M., Beck, K., Seo, S., Park, J. W., Lee, J. S., Lee, Y., & Kwon, J. S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.258 · Cited by 146
“…396.1 (±157.5) Treatment responder: 283.9 (±159.14) PANSS: treatment resistant: 104.3 (±10.6) Treatment responder: 50.7 (±5.8) No difference between treatment-resistant and controls Increased in treatment responder Howes et al (2013)b 29 (22/7) 29.3 (±7.5) 29 (26/3) 33.7 (±10.6) 5 Naive, 8…”
BackgroundResultInfluentialSelf-citationRole of basal ganglia neurocircuitry in the pathology of psychiatric disorders
Macpherson, T., & Hikida, T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12830 · Cited by 130
“More recently, alterations in striatal dopamine release were found to be particularly localized to the associative striatum, and are hypothesized to contribute to the misattribution of salience to certain environmental stimuli, associated with psychosis.(153,160,161) PET studies have also reported an increase in dopam…”
BackgroundAllen, P., Chaddock, C. A., Egerton, A., Howes, O. D., Bonoldi, I., Zelaya, F., Bhattacharyya, S., Murray, R., & McGuire, P. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040485 · Cited by 127
Self-citationPurves-Tyson, T. D., Weber-Stadlbauer, U., Richetto, J., Rothmond, D. A., Labouesse, M. A., Polesel, M., Robinson, K., Shannon Weickert, C., & Meyer, U. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0434-0 · Cited by 127
“Abnormal inflammatory processes in the midbrain may thus have a role in schizophrenia by contributing to presynaptic dopamine abnormalities [24, 25].”
InfluentialHistamine, Neuroinflammation and Neurodevelopment: A Review
Carthy, E. R., & Ellender, T. J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.680214 · Cited by 136
The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review
Dahoun, T., Trossbach, S. V., Brandon, N. J., Korth, C., & Howes, O. D. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.282 · Cited by 136
Self-citationKambeitz, J., Abi-Dargham, A., Kapur, S., & Howes, O. D. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.132308 · Cited by 115
“79,80 Taken with evidence for altered dopamine synthesis capacity in the nigra, 81 this suggests there is increased nigral dopamine function but no compensatory change in nigral D 2 /D 3 receptors.”
BackgroundSelf-citationJauhar, S., McCutcheon, R., Borgan, F., Veronese, M., Nour, M., Pepper, F., Rogdaki, M., Stone, J., Egerton, A., Turkheimer, F., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30268-2 · Cited by 114
Self-citationIncreased Macrophages and C1qA, C3, C4 Transcripts in the Midbrain of People With Schizophrenia
Purves-Tyson, T. D., Robinson, K., Brown, A. M., Boerrigter, D., Cai, H. Q., Weissleder, C., Owens, S. J., Rothmond, D. A., & Weickert, C. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02002 · Cited by 128
“Gender (M, F) (20,8) (11,4) (8,5) – (19,7) (9,4) (7,5) –”
Howes, O. D., Hird, E. J., Adams, R. A., Corlett, P. R., & McGuire, P. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.03.012 · Cited by 110
Self-citationGiannopoulou, I., Pagida, M. A., Briana, D. D., & Panayotacopoulou, M. T. (2018) · HORMONES · doi:10.1007/s42000-018-0007-7 · Cited by 112
“Heads up” for creatine supplementation and its potential applications for brain health and function
Candow, D. G., Forbes, S. C., Ostojic, S. M., Prokopidis, K., Stock, M. S., Harmon, K. K., & Faulkner, P. (2023) · Sports Medicine · doi:10.1007/s40279-023-01870-9 · Cited by 78
“…emission tomography and 1 H-magnetic resonance spectroscopy ( 1 H-MRS) to examine neurotransmitter systems such as serotonin [138], dopamine (e.g., Howes et al., [139]), glutamate [140], and GABA [141], the results of these studies have not significantly aided the development of novel therapies.”
BackgroundThe impact of leptin on perinatal development and psychopathology
Valleau, J. C., & Sullivan, E. L. (2014) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2014.05.001 · Cited by 102
Unexpected global impact of VTA dopamine neuron activation as measured by opto-fMRI
Lohani, S., Poplawsky, A. J., Kim, S.-G., & Moghaddam, B. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.102 · Cited by 89
“7, 8 Accordingly, with a few exceptions, 9, 10 human investigations of addictive disorders, 11 schizophrenia, 12–14 and mood disorders 15, 16 have primarily focused on functional magnetic resonance imaging (fMRI) activity in VTA innervated limbic regions as a measure of dopamine-related dysfunction.”
Joint sparse canonical correlation analysis for detecting differential imaging genetics modules
Fang, J., Lin, D., Schulz, S. C., Xu, Z., Calhoun, V. D., & Wang, Y. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw485 · Cited by 91
“, 1996) and dopamine synthesis capacity has been found related to schizophrenia and symptom severity(Howes et al., 2013).”
BackgroundThe dual hit hypothesis of schizophrenia: Evidence from animal models
Guerrin, C. G. J., Doorduin, J., Sommer, I. E., & de Vries, E. F. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.025 · Cited by 95
Dopamine, fronto-striato-thalamic circuits and risk for psychosis
Dandash, O., Pantelis, C., & Fornito, A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.08.020 · Cited by 84
Purves-Tyson, T. D., Owens, S. J., Rothmond, D. A., Halliday, G. M., Double, K. L., Stevens, J., McCrossin, T., & Shannon Weickert, C. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.257 · Cited by 80
Neural substrates of the impaired effort expenditure decision making in schizophrenia.
Huang, J., Yang, X.-H., Lan, Y., Zhu, C.-Y., Liu, X.-Q., Wang, Y.-F., Cheung, E. F. C., Xie, G.-R., & Chan, R. C. K. (2016) · Neuropsychology · doi:10.1037/neu0000284 · Cited by 69
Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Natesan, S., Turkheimer, F., Stone, J., Egerton, A., McGuire, P., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.07.003 · Cited by 75
“Secondary analyses were also conducted with substantia nigra, given prior findin gs of a relationship between psychotic symptoms and dopamine synthesis capacity in substantia nigra (15), and associative striatum and treatment response, based on prior literature (27).”
Self-citationLeucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 82
“Overall findings pinpoint the major dopamine alterations in schizophrenia to presynaptic function, affecting dopamine synthesis and release, and these alterations are correlated with the severity of psychotic symptoms, at least in studies of acutely ill patients 116–118 .”
Self-citationAvram, M., Brandl, F., Cabello, J., Leucht, C., Scherr, M., Mustafa, M., Leucht, S., Ziegler, S., & Sorg, C. (2019) · Brain · doi:10.1093/brain/awz093 · Cited by 70
Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models
Conn, K., Burne, T. H. J., & Kesby, J. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00542 · Cited by 69
Molecular mechanisms of psychiatric diseases
Blokhin, I. O., Khorkova, O., Saveanu, R. V., & Wahlestedt, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105136 · Cited by 69
Watanabe, Y., Tanaka, H., Tsukabe, A., Kunitomi, Y., Nishizawa, M., Hashimoto, R., Yamamori, H., Fujimoto, M., Fukunaga, M., & Tomiyama, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104619 · Cited by 66
“Recently, Howers et al [17] reported the same results using a post-mortem study, which revealed that tyrosine hydroxylase staining scores were significantly greater in the schizophrenia group at substantia nigra compared to in healthy controls and in vivo imaging using PET which showed that elevated dopamine synthesis…”
Sundberg, M., Pinson, H., Smith, R. S., Winden, K. D., Venugopal, P., Tai, D. J. C., Gusella, J. F., Talkowski, M. E., Walsh, C. A., Tegmark, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23113-z · Cited by 59
Salutogenic Architecture in Healthcare Settings
Golembiewski, J. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-04600-6_26 · Cited by 76
“Dopamine is interesting because it is directly implicated in many mental illnesses (Howes et al. 2013).”
BackgroundNeurobiological Determinants of Tobacco Smoking in Schizophrenia
Lucatch, A. M., Lowe, D. J. E., Clark, R. C., Kozak, K., & George, T. P. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00672 · Cited by 61
Axonal myelin decrease in the splenium in major depressive disorder
Williams, M. R., Sharma, P., Macdonald, C. L., Pearce, R. K. B., Hirsch, S. R., & Maier, M. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0904-4 · Cited by 55
Self-citationZhu, Y., Owens, S. J., Murphy, C. E., Ajulu, K., Rothmond, D. A., Purves-Tyson, T. D., Middleton, F. A., Webster, M. J., & Weickert, C. S. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.06.012 · Cited by 54
Neurobehavioral Consequences of Traffic-Related Air Pollution
Salvi, A., & Salim, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01232 · Cited by 52
Reductions in midbrain GABAergic and dopamine neuron markers are linked in schizophrenia
Purves-Tyson, T. D., Brown, A. M., Weissleder, C., Rothmond, D. A., & Weickert, C. S. (2021) · Molecular Brain · doi:10.1186/s13041-021-00805-7 · Cited by 53
MicroRNA schizophrenia: Etiology, biomarkers and therapeutic targets
Zhang, H.-C., Du, Y., Chen, L., Yuan, Z., & Cheng, Y. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105064 · Cited by 51
TRIMAGE: A dedicated trimodality (PET/MR/EEG) imaging tool for schizophrenia
Guerra, A. D., Ahmad, S., Avram, M., Belcari, N., Berneking, A., Biagi, L., Bisogni, M. G., Brandl, F., Cabello, J., Camarlinghi, N., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2017.11.007 · Cited by 51
“The dopamine system is the neurotransmitter system which has been most commonly associated with schizophrenia, under the hypothesis that schizophrenic patients undergo an increased dopamine synthesis capacity in the striatum as compared to healthy subjects [5].”
BackgroundGene-sex interactions in schizophrenia: focus on dopamine neurotransmission
Godar, S. C., & Bortolato, M. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00071 · Cited by 47
“…presynaptic DA content in the striatum may be the main biological signatures of psychotic disorders (Howes and Kapur, 2009; Fusar-Poli et al., 2011; Howes et al., 2011, 2012, 2013; Allen et al., 2012; Egerton et al., 2013; Stokes et al., 2013; Lataster et al., 2014; see Kuepper et al., 2012 and…”
BackgroundEffective Connectivity of Fronto-Striato-Thalamic Circuitry Across the Psychosis Continuum
Sabaroedin, K., Razi, A., Chopra, S., Tran, N., Pozaruk, A., Chen, Z., Finlay, A., Nelson, B., Allott, K., Álvarez‐Jiménez, M., et al. (2021) · Brain · doi:10.1016/j.biopsych.2021.02.887 · Cited by 48
Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia
Rice, M. W., Roberts, R. C., Meléndez‐Ferro, M., & Pérez‐Costas, E. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0901-y · Cited by 47
“The present study shows evidence of conspicuous subregion specific deficits in TH protein expression within the diencephalic sub-region of the SN/VTA, without neuronal loss.”
InfluentialDopamine Pharmacodynamics: New Insights
Lauretani, F., Giallauria, F., Testa, C., Zinni, C., Lorenzi, B., Zucchini, I., Salvi, M., Napoli, R., & Maggio, M. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105293 · Cited by 43
Cheng, C. P.-W., Chang, W. C., Lo, G. G., Chan, K. W. S., Lee, E. H. M., Hui, L. M. C., Suen, Y. N., Leung, Y. L., Yeung, K. M. P. A., Chen, S., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0740-x · Cited by 41
Self-citationAvram, M., Brandl, F., Knolle, F., Cabello, J., Leucht, C., Scherr, M., Mustafa, M., Koutsouleris, N., Leucht, S., Ziegler, S. I., et al. (2020) · Brain · doi:10.1093/brain/awaa296 · Cited by 41
Consensus on potential biomarkers developed for use in clinical tests for schizophrenia
Lin, P., Sun, J., Lou, X., Li, D., Shi, Y., Li, Z., Ma, P., Li, P., Chen, S., Jin, W., et al. (2022) · General Psychiatry · doi:10.1136/gpsych-2021-100685 · Cited by 41
Ariza-Salamanca, D. F., Corrales-Hernández, M. G., Pachón-Londoño, M. J., & Hernández-Duarte, I. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.993671 · Cited by 40
“Thus, when altered, an incongruent representation and interpretation of the external stimulus results in psychosis (Howes and Kapur, 2009; Fusar-Poli et al., 2010; Howes et al., 2013).”
BackgroundCircadian Clocks in the Regulation of Neurotransmitter Systems
Kiehn, J., Faltraco, F., Palm, D., Thome, J., & Oster, H. (2019) · Pharmacopsychiatry · doi:10.1055/a-1027-7055 · Cited by 42
Howes, O. D., Bonoldi, I., McCutcheon, R. A., Azis, M., Antoniades, M., Bossong, M. G., Modinos, G., Pérez, J. M., Stone, J. M., Santangelo, B., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0541-2 · Cited by 39
Self-citationvan der Pluijm, M., Wengler, K., Reijers, P. N., Cassidy, C., Joe, K. T. T., de Peuter, O. R., Horga, G., Booij, J., de Haan, L., & van de Giessen, E. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220780 · Cited by 35
Ultrastructural evidence for glutamatergic dysregulation in schizophrenia
Roberts, R. C., McCollum, L. A., Schoonover, K. E., Mabry, S. J., Roche, J. K., & Lahti, A. C. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.01.016 · Cited by 37
“Functional MRI reports show disturbed functional connectivity (Hadley et al 2014), which is correlated with increased dopamine synthesis capacity (Howes et al. 2013; Watanabe et al. 2014).”
BackgroundSubstantia nigra ultrastructural pathology in schizophrenia
Walker, C. K., Roche, J. K., Sinha, V., & Roberts, R. C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.004 · Cited by 36
Nigral stress-induced dopamine release in clinical high risk and antipsychotic-naïve schizophrenia
Tseng, H.-H., Watts, J. J., Kiang, M., Suridjan, I., Wilson, A. A., Houle, S., Rusjan, P. M., & Mizrahi, R. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx042 · Cited by 31
Impaired contextual fear-conditioning in MAM rodent model of schizophrenia
Gill, K. M., Miller, S. A., & Grace, A. A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.064 · Cited by 30
“Abnormal hippocampal activity in schizophrenia likely underlies the pathological alteration of the dopamine system (Abi-Dargham et al., 1998; Abi-Dargham et al., 2004; Abi-Dargham et al., 2009; Breier et al., 1997; Howes et al., 2013; Laruelle and Abi-Dargham, 1999).”
BackgroundArtiges, É., Leroy, C., Dubol, M., Prat, M., Pepin, A., Mabondo, A., de Beaurepaire, R., Beaufils, B., Korwin, J.-P., Galinowski, A., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw192 · Cited by 36
Vano, L. J., McCutcheon, R. A., Rutigliano, G., Kaar, S. J., Finelli, V., Nordio, G., Wellby, G., Sedlacik, J., Statton, B. K., Rabiner, E. A., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.06.013 · Cited by 29
Self-citationD’Ambrosio, E., Jauhar, S., Kim, S., Veronese, M., Rogdaki, M., Pepper, F., Bonoldi, I., Kotoula, V., Kempton, M. J., Turkheimer, F., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0570-6 · Cited by 29
Self-citationSchoonover, K. E., Queern, S. L., Lapi, S. E., & Roberts, R. C. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1523562 · Cited by 28
“Our sample size was small and as is typical for postmortem investigations, none of our patients were first episode and/or antipsychotic naïve (Howes et al. 2013; Schoonover et al. 2017).”
BackgroundGoto, S., Morigaki, R., Okita, S., Nagahiro, S., & Kaji, R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00022 · Cited by 29
“E), TH-positive dots, largely of the axonal fibers originating from the midbrain dopaminergic cells (Howes et al., 2013), were distributed in a differential manner to MEnk-positive dots.”
BackgroundMcCutcheon, R. A., Jauhar, S., Pepper, F., Nour, M. M., Rogdaki, M., Veronese, M., Turkheimer, F., Egerton, A., McGuire, P. K., Mehta, M. A., et al. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.04.004 · Cited by 29
Self-citationRabella, M., Grasa, E., Corripio, I., Romero, S., Mañanas, M. Á., Antonijoan, R. M., Münte, T. F., Pérez, V., & Riba, J. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.05.019 · Cited by 30
“Neuroimaging studies using (18)Fdopa have found excessive dopamine synthesis potential in this population (Howes et al., 2013).”
InfluentialMouri, A., Lee, H., Mamiya, T., Aoyama, Y., Matsumoto, Y., Kubota, H., Huang, W., Chiou, L., & Nabeshima, T. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15043 · Cited by 25
“This is supported by the finding of increased tyrosine hydroxylase (TH) in the substantia nigra of patients with schizophrenia (Howes et al., 2013).”
BackgroundAbi‐Dargham, A. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.003 · Cited by 25
Petty, A. E., Cui, X., Tesiram, Y. A., Kirik, D., Howes, O. D., & Eyles, D. W. (2019) · Schizophrenia · doi:10.1038/s41537-019-0074-z · Cited by 28
Self-citationKim, S., Shin, S. H., Santangelo, B., Veronese, M., Kang, S. K., Lee, J. S., Cheon, G. J., Lee, W., Kwon, J. S., Howes, O. D., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00879-0 · Cited by 25
Self-citationSportelli, L., Eisenberg, D. P., Passiatore, R., D’Ambrosio, E., Antonucci, L. A., Bettina, J. S., Chen, Q., Goldman, A. L., Gregory, M. D., Griffiths, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47456-5 · Cited by 24
Self-citationAssociation of Serotonin2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
Li, J., Hashimoto, H., & Meltzer, H. Y. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00058 · Cited by 25
“Stimulation of DA D2 receptors in the ventral and dorsal striatum can lead to delusions and hallucinations (5).”
BackgroundMabry, S. J., McCollum, L. A., Farmer, C. B., Bloom, E. S., & Roberts, R. C. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1615638 · Cited by 24
“A number of studies indicate increased dopamine activity, protein and/or mRNA levels (Toru et al. 1988; Howes et al. 2013; Williams et al. 2014; Schoonover et al. 2017), while others do not (Ichinose et al. 1994; Perez-Costas et al. 2012).”
Backgroundvan Hooijdonk, C. F. M., van der Pluijm, M., Bosch, I., van Amelsvoort, T., Booij, J., de Haan, L., Selten, J., & van de Giessen, E. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.12.008 · Cited by 23
Schoonover, K. E., McCollum, L. A., & Roberts, R. C. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.164 · Cited by 25
Tian, X., Richard, A. D., El-Saadi, M. W., Bhandari, A., Latimer, B., Savage, I. V., Holmes, K., Klein, R. L., Dwyer, D. S., Goeders, N. E., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0492-3 · Cited by 23
Borgus, J. R., Wang, Y., DiScenza, D. J., & Venton, B. J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00175 · Cited by 20
Impaired Dopamine Release and Latent Learning in Alzheimer’s Disease Model Zebrafish
Jarošová, R., Niyangoda, S. S., Hettiarachchi, P., & Johnson, M. A. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00484 · Cited by 20
Role of presynaptic phosphoprotein synapsin II in schizophrenia
Molinaro, L., Hui, P., Tan, M. L., & Mishra, R. K. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.260 · Cited by 20
D’Ambrosio, E., Dahoun, T., Pardiñas, A. F., Veronese, M., Bloomfield, M., Jauhar, S., Bonoldi, I., Rogdaki, M., Froudist‐Walsh, S., Walters, J., et al. (2019) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2019.07.005 · Cited by 23
Self-citationIncreased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia
Petty, A. E., Glass, L. J., Rothmond, D. A., Purves-Tyson, T. D., Sweeney, A., Kondo, Y., Kubo, S., Matsumoto, M., & Weickert, C. S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02541-8 · Cited by 21
“There is evidence of increased dopaminergic activity in the midbrain of people with schizophrenia [36, 47, 48].”
BackgroundSalzman, G., Kim, J. T., Horga, G., & Wengler, K. (2021) · Journal of Visualized Experiments · doi:10.3791/62493 · Cited by 20
Angelescu, I., Kaar, S. J., Marques, T. R., Borgan, F., Veronesse, M., Sharman, A., Sajjala, A., Deakin, J. F. W., Hutchison, J., Large, C. H., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221122031 · Cited by 18
“A region-of-interest (ROI) analysis was conducted to measure Kicer (Ki in previous publications; Howes et al., 2013), using MATLAB R2018b (MATLAB, 2018), SPM12 and Piwave (Turkheimer et al., 1999).”
BackgroundMethodInfluentialSelf-citationBiological Psychiatry and Psychopharmacology
Fountoulakis, K. N., Nimatoudis, I., & Stahl, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18323-3_13 · Cited by 17
Turk, K. W., Flanagan, M. E., Josephson, S., Keene, C. D., Jayadev, S., & Bird, T. D. (2017) · The Cerebellum · doi:10.1007/s12311-017-0882-5 · Cited by 16
“Two blinded, independent neuropathologists performed TH scoring/analysis limited to substantia nigra dopaminergic neurons at × 400 magnification following published protocol from studies of schizophrenia and depression [29], where 0 was rated as no staining, 1 was equivalent to moderate cytoplasmic staining, and 2 was…”
BackgroundMethodResultInfluentialHanson, K. L., Weir, R. K., Iosif, A., de Water, J. V., Carter, C. S., McAllister, A. K., Bauman, M. D., & Schumann, C. M. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.01.003 · Cited by 19
Magnetic resonance imaging of the dopamine system in schizophrenia – A scoping review
Schulz, J., Zimmermann, J., Sorg, C., Menegaux, A., & Brandl, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.925476 · Cited by 14
Histological examination of choroid plexus epithelia changes in schizophrenia
Williams, M. R., Macdonald, C. M., & Turkheimer, F. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.016 · Cited by 17
Self-citationYamamoto, Y., Takahata, K., Kubota, M., Takano, H., Takeuchi, H., Kimura, Y., Sano, Y., Kurose, S., Ito, H., Mimura, M., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117543 · Cited by 15
Kaar, S. J., Angelescu, I., Nour, M. M., Marques, T. R., Sharman, A., Sajjala, A., Hutchison, J., McGuire, P. K., Large, C. H., & Howes, O. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06216-3 · Cited by 14
Self-citationThe Placebo Effect in Psychosis: Why It Matters and How to Measure It
Hird, E., Diederen, K. M. J., Leucht, S., Jensen, K. B., & McGuire, P. K. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2023.02.008 · Cited by 15
Self-citation
Metadata
- Authors
- Howes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., & Turkheimer, F.
- Affiliations
- King's College London (GB)
- Hammersmith Hospital (GB)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-03
- Volume
- 136
- Issue
- 11
- Pages
- 3242-3251
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3808688
- OpenAlex
- W2148486359
- Cited by
- 198
- References
- 81
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 11 · 2023: 23 · 2022: 19 · 2021: 15 · 2020: 24 · 2019: 20 · 2018: 14 · 2017: 10 · 2016: 16 · 2015: 8 · 2014: 11
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Starr Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- schizophrenia, major depressive disorder, midbrain dopamine, substantia nigra, striatum, dopamine synthesis capacity, tyrosine hydroxylase, 18F-DOPA PET, dopaminergic dysfunction, symptom severity, postmortem brain, dopaminergic neurons, dopamine signaling, neuroimaging biomarkers
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Dihydroxyphenylalanine, Dopamine, Female, Humans, Male, Middle Aged, Schizophrenia, Substantia Nigra, Tissue Banks, Tyrosine 3-Monooxygenase, Dopamine Agents, Neostriatum, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.